Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 15,368 as of Monday, May 20, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,885 issues advancing vs. 1,048 declining with 118 unchanged. The Drugs industry currently sits down 0.15 versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Pharmacyclics Incorporated ( PCYC), down 4.30, Amgen ( AMGN), down 3.34, Allergan ( AGN), down 1.51, Valeant Pharmaceuticals International ( VRX), down 1.39 and Celgene Corporation ( CELG), down 1.27. A company within the industry that increased today was Actavis ( ACT), up 2.39. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.32 (-0.6%) to $54.18 on light volume Thus far, 303,421 shares of Sanofi exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $54.00-$54.40 after having opened the day at $54.14 as compared to the previous trading day's close of $54.50. Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $145.4 billion and is part of the health care sector. The company has a P/E ratio of 29.1, above the S&P 500 P/E ratio of 17.7. Shares are up 15.0% year to date as of the close of trading on Friday. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.